secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2026-10-02T20:30:32+00:00
Accession:  0001493152-26-045527
Event type: leadership
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Cingulate extends CMO Matthew Brams' trial period to Dec 31, 2026 at $400,000 base salary
--------------------------------------------------------------------------------

- Amendment No. 2 to the employment agreement of Matthew N. Brams, EVP and Chief Medical Officer, extends his Trial Period from September 30, 2026 to December 31, 2026.
- Brams' annual base salary is set at $400,000 for 100% full-time effort, effective January 1, 2026 through December 31, 2026.
- At the end of the Trial Period, CEO Shane J. Schaffer has sole discretion to keep Brams full-time or return him to a part-time role at a lower base salary.
- All other provisions of the January 1, 2026 employment agreement remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315226045527/0001493152-26-045527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315226045527/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-045527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer